Dr. Paulovich completed a residency in Internal Medicine at Massachusetts General Hospital and a fellowship in Oncology at Dana-Farber Cancer Institute. She completed her graduate training in genetics with Dr. Lee Hartwell at University of Washington and postdoctoral training in genomics at the Massachusetts Institute of Technology with Dr. Eric Lander. As an oncologist, Dr. Paulovich was struck by the paucity of quantitative assays for measuring clinically relevant phenotypes in her patients, and the limitations that this put on her ability to practice “personalized medicine.” Out of these experiences, she became passionate about developing technologies and strategies for translation of novel diagnostics and therapeutics to enable precision medicine. Over the past 18 years, Dr. Paulovich's interdisciplinary laboratory has focused on applying proteogenomic approaches to understanding cancer biology and laying the groundwork for the clinical translation of novel diagnostics based on targeted, multiple reaction monitoring (MRM) mass spectrometry.
Proteogenomics: The Next Horizon in Precision Oncology
This presentation will discuss the added value of proteogenomics to the current genome-driven approach to precision oncology, and summarize the growing incorporation of targeted proteomic measurements based on selected/multiple reaction monitoring (SRM/MRM) mass spectrometry into clinical trials and the clinical laboratory.